Physician profile
David Braun
NPI 1477991933
$61,716.34
in general payments reported to CMS, 2019-2025
9 companies · $24K in 2025
The $24K reported for 2025 was more than what 90% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2021: $6,060 · 2022: $12K · 2023: $16K · 2024: $3,961 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Travel and Lodging: $8,917 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,490 · Honoraria: $4,290 · Food and Beverage: $1,267 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,100.00 |
| Travel and Lodging | $8,916.95 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,490.00 |
| Honoraria | $4,290.00 |
| Food and Beverage | $1,267.08 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $25,604.57 | 2019-2025 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $11,773.00 | 2021-2025 | |
| Abbvie INC. | $10,800.00 | 2022 | |
| Eisai INC. | $9,379.32 | 2024-2025 | |
| Pfizer INC. | $1,890.00 | 2023 | |
| Daiichi Sankyo INC. | $1,687.50 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $538.70 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $43.25 | 2025 | Enhertu |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Braun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.